The HIGH BCR-ABL1 GENE PERCENTAGE AT TIME OF PRESENTATION: A TOOL TO PREDICT FAILURE IN ACHIEVING EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML): A TERTIARY CARE CENTER EXPERIENCE
Objective: To determine the relationship of baseline quantitative BCR ABL1 gene percentage and therapeutic response i.e. Early Molecular Response (EMR) at 3 months with first generation Tyrosine kinase inhibitors (Imatinib) in patients with Chronic Myeloid Leukemia (CML) in chronic phase (CP). St...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Army Medical College Rawalpindi
2021
|
| Sujets: | |
| Accès en ligne: | https://doi.org/10.51253/pafmj.v71iSuppl-1.3891 https://doaj.org/article/846cf15589294effabd70c5c81935f9c |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|